Mobile Stroke Units: Does Bringing the CT to the Patient Help

The short answer

For patients eligible for clot-dissolving drugs, bringing the CT scanner to the patient does appear to help. Mobile stroke units, which are specialized ambulances carrying a CT scanner, a point-of-care lab, and the ability to give thrombolytic medication before hospital arrival, cut the time from stroke onset to treatment by roughly half an hour and improve the odds of recovering with little or no disability. That is why the 2026 American Heart Association and American Stroke Association guideline now gives mobile stroke units their strongest endorsement, a Class 1, Level A recommendation, for eligible patients where such units are available. What the evidence does not yet settle is whether the model is affordable and reachable everywhere it might be wanted. This article is educational and is not medical advice.

Why minutes matter in ischemic stroke

In acute ischemic stroke, a clot blocks blood flow and brain tissue begins to die quickly. The standard early treatment is intravenous thrombolysis, a drug that dissolves the clot, and its benefit shrinks with every passing minute. The logic of a mobile stroke unit is to move the two decisive steps, diagnosis and the start of treatment, out of the hospital and onto the road. A CT scan on board rules out bleeding in the brain, which is the one finding that must be excluded before a thrombolytic can be given safely, and the crew can start the drug at the scene rather than after a hospital handoff. The biology of the drug is unchanged; what changes is how fast it reaches the patient.

What the trials actually show

The 2026 guideline rests its recommendation on two large studies. The BEST-MSU trial, published in the New England Journal of Medicine in 2021, compared care aboard a mobile stroke unit with conventional emergency medical services across several U.S. cities using an alternating-week design rather than patient-level randomization. Among patients eligible for the thrombolytic tPA, the median time from stroke onset to treatment was 72 minutes in the mobile-unit group versus 108 minutes with standard ambulances. Nearly all eligible mobile-unit patients received the drug, 97.1 percent versus 79.5 percent, and at 90 days a larger share had reached a modified Rankin Scale score of 0 or 1, meaning no symptoms or no meaningful disability: 55.0 percent versus 44.4 percent. Mortality at 90 days was numerically lower in the mobile-unit group, 8.9 percent versus 11.9 percent, and the investigators reported no signal that faster treatment came at the cost of safety.

The Berlin-based B_PROUD study, published in JAMA in 2021, pointed the same direction. It was a prospective, nonrandomized study that compared patients when a mobile stroke unit was dispatched against those who received a conventional ambulance, and it found a favorable shift across the whole distribution of disability scores at three months, not only at the best end of the scale. Two independent health systems, on two continents, converging on a benefit is the kind of consistency that moves a recommendation to Level A.

What "Class 1, Level A" means, and what it does not

A Class 1, Level A recommendation is the highest tier a guideline offers: strong benefit, supported by high-quality evidence from more than one study. It is worth being precise about the scope of the claim, though. The benefit is demonstrated in patients eligible for thrombolysis who are reached by a unit that already exists. The guideline endorses using a mobile stroke unit over conventional services where such a unit is available. That phrasing carries weight, because availability is exactly the variable that trials do not resolve. A recommendation that a tool works when present is not the same as a recommendation that every region should buy one.

The cost and access questions the evidence leaves open

Mobile stroke units are expensive. The published trials were not designed to measure cost, but separate reporting and modeling describe capital and operating figures on the order of hundreds of thousands to about a million dollars to launch and a comparable sum to run each year, reflecting the on-board scanner, staffing, and maintenance. Modeling studies suggest they can be cost-effective, but that finding depends heavily on context. The favorable economics appear in dense urban catchments where a single unit reaches enough eligible strokes per year to justify its standing cost. Most of the trial evidence, and most operating units, sit in exactly those settings.

That urban concentration is the crux of the equity problem. Rural areas, where ambulance transport times are longest and a prehospital scanner could in principle help most, are the least studied and the hardest to serve, because low population density means each unit treats fewer patients for the same fixed cost. There is a real risk that a technology validated in cities widens rather than narrows the gap between urban and rural stroke outcomes if deployment simply follows where it is easiest to fund. The trial populations also underrepresent some groups, so how the benefit generalizes across the full range of communities is a genuine open question rather than a settled one.

How to read the endorsement

The honest picture is that the "does it help" question and the "should we build them everywhere" question have different answers. On the first, the evidence is now strong: for the right patient, in a place where a unit is running, bringing the CT to the patient shortens the path to treatment and improves outcomes, and the 2026 guideline reflects that. On the second, the answer is local. Whether a given city or region should invest depends on its stroke volume, its existing transport times, and how a new unit changes access for the people currently served worst, not best. A guideline can tell you a tool works. It cannot tell you, from a distance, whether it is the right use of a particular community's finite resources.